A phase I randomized trial to assess the effect on skin infiltrate thickness and tolerability of topical phosphodiesterase inhibitors in the treatment of psoriasis vulgaris using a modified psoriasis plaque test

2016 ◽  
Vol 175 (3) ◽  
pp. 479-486 ◽  
Author(s):  
S.D. Snape ◽  
W. Wigger-Alberti ◽  
U.M. Goehring
2012 ◽  
Vol 32 (9) ◽  
pp. 613-619
Author(s):  
Catherine Queille-Roussel ◽  
Vibeke Hoffmann ◽  
Cecilia Ganslandt ◽  
Klaus Krog Hansen

2020 ◽  
Vol 41 ◽  
pp. 102015 ◽  
Author(s):  
Lindsey Wooliscroft ◽  
Ghadah Altowaijri ◽  
Andrea Hildebrand ◽  
Mary Samuels ◽  
Barry Oken ◽  
...  

Vaccine ◽  
2010 ◽  
Vol 28 (38) ◽  
pp. 6221-6227 ◽  
Author(s):  
Jiang Wu ◽  
Shu-Zhen Liu ◽  
Shan-Shan Dong ◽  
Xiao-Ping Dong ◽  
Wu-Li Zhang ◽  
...  
Keyword(s):  
Phase I ◽  

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 12001-12001
Author(s):  
Thomas J. Smith ◽  
Vincent Chung ◽  
Mark T. Hughes ◽  
Marianna Koczywas ◽  
Nilofer Saba Azad ◽  
...  

12001 Background: The purpose of this study was to test a Palliative Care Intervention for patients with solid tumors enrolled in phase I therapeutic trials. Methods: This randomized trial compared patients accrued to phase I Clinical Trials in groups of Usual Care compared to a Palliative Care Intervention (PCI) in two comprehensive cancer centers. The PCI included assessment of quality of life (QOL) and symptoms, an interdisciplinary meeting to discuss the care plan, including goals of care, and two nurse-delivered teaching sessions. Subjects (n=479) were followed for 24 weeks, with 12 weeks as the primary outcome point. Results: Outcomes revealed that relative to Usual Care, PCI subjects showed less Psychological Distress (1.9 in Intervention and 1.2 in Control pts, p=0.03) and a trend toward improved QOL (3.7 versus 1.6, p=0.07), with differences between sites. We observed high rates of symptom-management admissions (41.3%) and low rates of Advance Directive completion (39%), and use of supportive care services including hospice (30.7%, for only1.2 months duration), despite a median survival for all patients in both groups of 10.1 months from initiating a phase 1 study until death. Patient satisfaction with oncology care was already high at baseline, and we did not see clinically significant changes in those scores by week 12. Conclusions: Palliative care interventions can improve QOL outcomes and distress for patients participating in phase 1 trials. Greater integration of PC is needed to provide quality care to these patients and to support transitions from treatment to supportive care, especially at the end of life. Clinical trial information: NCT01828775 .


Neurology ◽  
2014 ◽  
Vol 83 (5) ◽  
pp. 413-425 ◽  
Author(s):  
E. Y. Uc ◽  
K. C. Doerschug ◽  
V. Magnotta ◽  
J. D. Dawson ◽  
T. R. Thomsen ◽  
...  

2017 ◽  
Vol 30 (2) ◽  
pp. 102-114 ◽  
Author(s):  
Walter Wigger-Alberti ◽  
Ragna Williams ◽  
Yi-Ling von Mackensen ◽  
Maciej Hoffman-Wecker ◽  
Ulrike Grossmann ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document